Medicare Enrolled

Dr. Bibas Reddy, D.O.

Hematology & Oncology · Fort Worth, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Mixed engagement
800 W MAGNOLIA AVE, Fort Worth, TX 76104
8177597000
In practice since 2007 (18 years)
NPI: 1457577017 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Reddy from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Reddy? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Reddy

Dr. Bibas Reddy is a hematology & oncology specialist in Fort Worth, TX, with 18 years of NPI registration. Based on federal Medicare data, Dr. Reddy performed 54,029 Medicare services across 1,555 unique beneficiaries.

Between the years covered by Open Payments, Dr. Reddy received a total of $14,097 from 54 pharmaceutical and/or device companies across 160 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Reddy is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice ▲ Top 17% volume in TX $14,097 industry payments

Medicare Practice Summary

Medicare Utilization ↗
54,029
Medicare services
Top 17% in TX for hematology & oncology
1,555
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,002 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Filgrastim injection (Nivestym) for white blood cells 27,961 $0 $2
Anti-nausea injection (fosaprepitant) 15,900 $0 $5
Dexamethasone injection (steroid) 2,302 $0 $5
Anti-nausea injection (Aloxi/palonosetron) 1,780 $1 $52
Epoetin alfa injection (Procrit) for anemia 1,760 $6 $28
Injection of additional new drug or substance into vein 489 $12 $70
Office visit, established patient (30-39 min) 456 $94 $275
Office visit, established patient, complex (40-54 min) 298 $138 $350
Administration of chemotherapy into vein, 1 hour or less 294 $101 $412
Injection, cisplatin, powder or solution, 10 mg 273 $2 $20
Injection, fluorouracil, 500 mg 247 $2 $5
Office visit, established patient (20-29 min) 218 $63 $175
Injection, carboplatin, 50 mg 202 $2 $60
Drug injection, under skin or into muscle 188 $11 $60
Ct scan of chest with contrast 158 $57 $401
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less 155 $22 $100
COVID-19 test, self-administered 152 $12 $30
Injection, diphenhydramine hcl, up to 50 mg 125 $1 $10
Injection, magnesium sulfate, per 500 mg 110 $1 $10
Administration of chemotherapy into vein, each additional hour 90 $21 $93
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 88 $47 $190
CT scan of abdomen and pelvis with contrast 80 $162 $681
Administration of additional new drug or substance into vein, 1 hour or less 79 $49 $202
Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month 74 $48 $160
Hospital follow-up visit, high complexity 71 $93 $250
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour 64 $15 $60
Ct scan of soft tissue of neck with contrast 51 $83 $399
Nuclear medicine study from skull base to mid-thigh with ct scan 51 $1,108 $4,069
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries 44 $101 $450
New patient office visit, complex (60-74 min) 43 $164 $500
Hospital follow-up visit, moderate complexity 41 $62 $175
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg 39 $1 $5
Infusion, normal saline solution , 1000 cc 25 $2 $20
Infusion into a vein for hydration, 31-60 minutes 23 $26 $155
Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month 20 $37 $120
Mri scan of brain before and after contrast 18 $158 $785
CT scan of chest, without contrast 18 $48 $300
Advance care planning consultation, first 30 min 16 $65 $250
Initial hospital admission, high complexity 15 $135 $500
Smoking and tobacco use intensive counseling, 4-10 minutes 11 $14 $30
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.7% high complexity
96.5% medium
2.8% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$14,097
Total received (2018-2024)
Avg $2,014/year across 7 years
Top 26% in TX for hematology & oncology
54
Companies
160
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,418 (38.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$4,994 (35.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,685 (26.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,853
2023
$5,826
2022
$335
2021
$1,607
2020
$2,542
2019
$685
2018
$1,249

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novocure Inc.
$4,693
AstraZeneca Pharmaceuticals LP
$3,824
Celgene Corporation
$348
Takeda Pharmaceuticals U.S.A., Inc.
$323
E.R. Squibb & Sons, L.L.C.
$302
Lilly USA, LLC
$278
Sirtex Medical Inc
$258
Puma Biotechnology, Inc.
$233
GlaxoSmithKline, LLC.
$226
Janssen Biotech, Inc.
$220
Merck Sharp & Dohme Corporation
$214
Clovis Oncology, Inc.
$189
Ipsen Biopharmaceuticals, Inc
$176
Stemline Therapeutics Inc.
$163
Tempus AI, Inc
$159
Foundation Medicine, Inc.
$144
Novartis Pharmaceuticals Corporation
$141
Eisai Inc.
$138
Incyte Corporation
$138
PUMA BIOTECHNOLOGY, INC.
$136
Monteris Medical Corporation
$135
Melinta Therapeutics, LLC
$124
Blueprint Medicines Corporation
$119
Daiichi Sankyo Inc.
$115
AbbVie, Inc.
$110
Regeneron Pharmaceuticals, Inc.
$104
Amgen Inc.
$97
Teva Pharmaceuticals USA, Inc.
$92
Merck Sharp & Dohme LLC
$77
Gilead Sciences, Inc.
$70
Regeneron Healthcare Solutions, Inc.
$68
SANOFI-AVENTIS U.S. LLC
$65
TG THERAPEUTICS, INC.
$50
Kite Pharma, Inc.
$50
ARRAY BIOPHARMA INC
$49
ABBVIE INC.
$46
Astellas Pharma US Inc
$42
Exelixis Inc.
$38
Boehringer Ingelheim Pharmaceuticals, Inc.
$33
GENZYME CORPORATION
$33
Epizyme, Inc.,
$31
Bayer HealthCare Pharmaceuticals Inc.
$28
Karyopharm Therapeutics Inc.
$27
Acrotech Biopharma LLC
$26
Genmab U.S., Inc.
$23
PFIZER INC.
$22
Genentech USA, Inc.
$18
Alexion Pharmaceuticals, Inc.
$16
Cumberland Pharmaceuticals, Inc.
$15
EMD Serono, Inc.
$15
MENARINI SILICON BIOSYSTEMS, INC.
$15
Seattle Genetics, Inc.
$15
MorphoSys, US Inc.
$14
Tactile Systems Technology Inc
$14
Top 3 companies account for 62.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · AYVAKIT · Abraxane · Avastin · BELEODAQ · BENDEKA · Bavencio · CYRAMZA · Cabometyx · Cellsearch · DARZALEX · ELAHERE · ELITEK · ENHERTU · ERBITUX · ERLEADA · Enhertu · Erleada · FLEXITOUCH · FRUZAQLA · GILOTRIF · IMFINZI · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · NERLYNX · NINLARO · Nerlynx · Neulasta · Neuroblate · Nplate · OJJAARA · OPDIVO · OPDUALAG · Onivyde · Optune · Orserdu · PLUVICTO · Padcev · Pomalyst · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · Rezzayo · Rubraca · SANCUSO · SIR-Spheres Microspheres · SOLIRIS · SPRYCEL · Stivarga · TAGRISSO · TAXOTERE · TAZVERIK · Tivdak · UKONIQ · VELCADE · VENCLEXTA · VERZENIO · Venclexta · XALKORI · XPOVIO · XTANDI · Xtandi · Yescarta · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (38%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $26 per 100 Medicare services performed
Looking for a hematology & oncology specialist in Fort Worth?
Compare hematology & oncology specialists in the Fort Worth area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
47
Per 100K population
2.2
County median income
$81,905
Nearest hospital
JPS HEALTH NETWORK
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Reddy is a mixed practice specialist, with above-average Medicare volume (top 17% in TX), with mixed engagement industry engagement, with 18 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Reddy experienced with filgrastim injection (nivestym) for white blood cells?
Based on Medicare claims data, Dr. Reddy performed 27,961 filgrastim injection (nivestym) for white blood cells services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Reddy receive payments from pharmaceutical companies?
Yes. Dr. Reddy received a total of $14,097 from 54 companies across 160 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Reddy's costs compare to other hematology & oncology specialists in Fort Worth?
Dr. Reddy's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Reddy) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →